PROM1 and cancer: They prepared highly biocompatible nanoparticles of PCAD-DMSN@DOX, an RNA aptamer targeting a cancer stem cell (CSC) marker that covalently binds to the carboxyl group of DOX to produce CD133-PCAD-DMSN@DOX.